Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms Abstract #1484

Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.
Aim(s): In order to resolve this contradiction, we performed a systematic search in PubMed.
Materials and methods: Systematic search was carried out using key words “appendix or appendiceal”, “carcinoid or neuroendocrine tumors”, “survival” and “registry or register”. We accessed the row data from Surveillance, Epidemiology and End Results Program (SEER) and received recent data from Cancer Registry of Norway (CRN).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Maike Nieser
Keywords: NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1490 Even Malignant Appendiceal Neuroendocrine Tumors Exhibit No Recurrent Chromosomal Alterations
Introduction: Neuroendocrine tumors (NETs) of the midgut are located in the ileum (iNET), caecum or appendix (aNET). Despite of the similar origin, NETs of the ileum and the appendix behave remarkably different. iNETs show high malignant potential, which manifests with early lymph node or liver metastases. Genetically, the loss of chromosome 18 (Ch18) in 60-74% of cases is the most frequent alteration in iNETs. aNETs are often incidental findings, rarely show metastases, and no chromosomal alterations are known.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Maike Nieser
Keywords: NET
#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#562 Expression of Chromosome 18 Related Tumor Suppressor Proteins in Ileal Neuroendocrine Tumors
Introduction: The genetic alterations in ileal neuroendocrine tumors (iNETs) are poorly
characterized. The most frequent chromosomal aberration is the loss of one
chromosome 18 in iNETs, however, the relevance of this alteration is unclear.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. Tobias Henopp
#565 Proliferative Activity is Not Associated with Tumor Aggressiveness in Ileal Neuroendocrine Tumors
Introduction: The accuracy of the new WHO grading system for neuroendocrine neoplasms has not yet been validated for ileal neuroendocrine tumors (iNETs).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Tobias Henopp